新型耐药结核病 6 个月疗程，美国。
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
出版信息
Emerg Infect Dis. 2021 Jan;27(1):332-4. doi: 10.3201/eid2701.203766. Epub 2020 Nov 23.
Abstract
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
摘要
美国食品和药物管理局批准了一种为期 6 个月的普托马尼德、贝达喹啉和利奈唑胺治疗方案，用于广泛耐药或耐多药结核病，此前南非的一项试验显示，治疗后 6 个月的有效率为 90%。我们报告了一位使用较低剂量利奈唑胺完成该方案的患者。
相似文献
1
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.新型耐药结核病 6 个月疗程，美国。
Emerg Infect Dis. 2021 Jan;27(1):332-4. doi: 10.3201/eid2701.203766. Epub 2020 Nov 23.
2
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.贝达喹啉、普托马尼德和利奈唑胺治疗南非、格鲁吉亚和菲律宾广泛耐药结核病的成本效益。
BMJ Open. 2021 Dec 3;11(12):e051521. doi: 10.1136/bmjopen-2021-051521.
3
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.贝达喹啉、普托马尼德和利奈唑胺在美国的应用：使用新型全口服治疗方案治疗利福平耐药或利福平不耐受结核病的经验。
Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312.
4
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.下一代二芳基喹啉类药物提高贝达喹啉和新型噁唑烷酮类药物 TBI-223 方案在小鼠结核病模型中的杀菌活性。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0003523. doi: 10.1128/aac.00035-23. Epub 2023 Mar 15.
5
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.在欧洲，利福平耐药结核病的贝达喹啉、普托马尼德、利奈唑胺和莫西沙星（BPaL（M））方案的药物供应和耐药检测情况。
Clin Microbiol Infect. 2024 Sep;30(9):1197.e1-1197.e4. doi: 10.1016/j.cmi.2024.03.009. Epub 2024 Mar 13.
6
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.贝达喹啉和利奈唑胺联合普托马尼治疗耐药结核病的前瞻性队列比较。
Int J Tuberc Lung Dis. 2021 Jun 1;25(6):453-460. doi: 10.5588/ijtld.21.0035.
7
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.贝达喹啉联合利奈唑胺或莫西沙星与吡嗪酰胺对鼠结核模型的新型方案的贡献。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00021-19. Print 2019 May.
8
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.耐多药结核分枝杆菌感染患者经贝达喹啉、德拉马尼和利奈唑胺治疗后出现无菌性结核性肉芽肿。
BMJ Case Rep. 2021 Dec 7;14(12):e245612. doi: 10.1136/bcr-2021-245612.
9
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.贝达喹啉、普托马尼和利奈唑胺新短程方案治疗利福平耐药结核病的安全性和耐受性：一项个体患者数据荟萃分析。
Clin Infect Dis. 2024 Mar 20;78(3):730-741. doi: 10.1093/cid/ciad653.
10
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.新型联合方案贝达喹啉或 TBAJ-587 联合 GSK2556286 和 TBA-7371 在结核分枝杆菌感染小鼠模型中的杀菌和灭菌活性。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0156223. doi: 10.1128/aac.01562-23. Epub 2024 Feb 20.
引用本文的文献
1
Pisces: A multi-modal data augmentation approach for drug combination synergy prediction.双鱼座：一种用于药物组合协同作用预测的多模态数据增强方法。
Cell Genom. 2025 Jul 9;5(7):100892. doi: 10.1016/j.xgen.2025.100892. Epub 2025 Jun 3.
2
Novel six-month all oral treatment of pre-extensively drug-resistant tuberculosis in Canada: New treatment options present new implementation challenges.加拿大新型六个月全口服治疗广泛耐药前结核病：新的治疗方案带来新的实施挑战。
Can Commun Dis Rep. 2023 Jan 5;49(1):15-20. doi: 10.14745/ccdr.v49i01a04.
3
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.新型联合方案贝达喹啉或 TBAJ-587 联合 GSK2556286 和 TBA-7371 在结核分枝杆菌感染小鼠模型中的杀菌和灭菌活性。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0156223. doi: 10.1128/aac.01562-23. Epub 2024 Feb 20.
4
Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone.塞拉利昂耐多药结核病的分子决定因素。
Microbiol Spectr. 2024 Mar 5;12(3):e0240523. doi: 10.1128/spectrum.02405-23. Epub 2024 Jan 30.
5
Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline.手性转移试剂在提高抗结核药物贝达喹啉合成中的立体选择性和产率方面的应用。
Org Process Res Dev. 2023 Oct 13;27(11):2146-2159. doi: 10.1021/acs.oprd.3c00287. eCollection 2023 Nov 17.
6
Rifampin Mono-Resistant Tuberculosis in New York City, 2010-2021: A Retrospective Case Series.2010 - 2021年纽约市耐利福平肺结核：一项回顾性病例系列研究
Open Forum Infect Dis. 2023 Nov 21;10(11):ofad534. doi: 10.1093/ofid/ofad534. eCollection 2023 Nov.
7
Exploring the potential of multi-target-directed ligands for tuberculosis treatment.探索多靶点导向配体在结核病治疗中的潜力。
Ther Adv Infect Dis. 2023 Jul 15;10:20499361231188039. doi: 10.1177/20499361231188039. eCollection 2023 Jan-Dec.
8
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.贝达喹啉、普托马尼德和利奈唑胺在美国的应用：使用新型全口服治疗方案治疗利福平耐药或利福平不耐受结核病的经验。
Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312.
9
FLASH-TB: an Application of Next-Generation CRISPR to Detect Drug Resistant Tuberculosis from Direct Sputum.FLASH-TB：一种利用下一代 CRISPR 技术从直接痰液中检测耐多药结核病的应用。
J Clin Microbiol. 2023 Apr 20;61(4):e0163422. doi: 10.1128/jcm.01634-22. Epub 2023 Apr 3.
10
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.下一代二芳基喹啉类药物提高贝达喹啉和新型噁唑烷酮类药物 TBI-223 方案在小鼠结核病模型中的杀菌活性。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0003523. doi: 10.1128/aac.00035-23. Epub 2023 Mar 15.
本文引用的文献
1
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.耐多药肺结核的治疗。
N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.
2
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.耐药结核病治疗。美国胸科学会/美国疾病控制与预防中心/欧洲呼吸学会/美国感染病学会临床实践指南。
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
3
WHO global progress report on tuberculosis elimination.世界卫生组织结核病消除全球进展报告。
Lancet Respir Med. 2020 Jan;8(1):19. doi: 10.1016/S2213-2600(19)30418-7. Epub 2019 Nov 6.
4
Pretomanid: First Approval.苯并异噻唑酮（pretomanid）：首次批准。
Drugs. 2019 Nov;79(16):1797-1803. doi: 10.1007/s40265-019-01207-9.
5
Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.使用数学建模和模拟优化莫西沙星和利奈唑胺治疗结核病的剂量。
Int J Antimicrob Agents. 2019 Mar;53(3):275-283. doi: 10.1016/j.ijantimicag.2018.10.012. Epub 2018 Oct 29.
6
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.耐多药结核病患者分离株中对氯法齐明和贝达喹啉的原发性耐药情况。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00239-17. Print 2017 Jun.
7
The Role of Therapeutic Drug Monitoring in Mycobacterial Infections.治疗药物监测在分枝杆菌感染中的作用。
Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TNMI7-0029-2016.
8
Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.利奈唑胺谷浓度与慢性广泛耐药结核病治疗中与线粒体毒性相关的不良事件相关。
EBioMedicine. 2015 Oct 9;2(11):1627-33. doi: 10.1016/j.ebiom.2015.09.051. eCollection 2015 Nov.
9
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.用于确定结核病治疗最佳利奈唑胺方案的临床前评估
mBio. 2015 Nov 3;6(6):e01741-15. doi: 10.1128/mBio.01741-15.
10
Linezolid for treatment of chronic extensively drug-resistant tuberculosis.利奈唑胺治疗慢性广泛耐药结核病。
N Engl J Med. 2012 Oct 18;367(16):1508-18. doi: 10.1056/NEJMoa1201964.
Zotero 插件